News
Read the latest news from Ariceum
© Ariceum Therapeutics
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Ariceum Therapeutics Doses First Patient in SANTANA-225 Phase 1/2 Clinical Trial of 225Ac-SSO110 in Patients with Extensive-Stage Small Cell Lung Cancer or Merkel Cell Carcinoma
225Ac-SSO110 has received U.S. FDA Orphan Drug Designation Initial safety data from SANTANA-225 in ES-SCLC and MCC expected in 2026 Potential to address a broad range of neuroendocrine cancers Berlin, Germany, 11 November 2025 – Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in cancer care, today announced that the first patient […]
Ariceum Therapeutics and Nusano Announce Multi-Isotope Supply Agreement
Agreement includes Actinium-225 (Ac-225) and Lutetium-177 (Lu-177) to support Ariceum’s therapeutic programs BERLIN, Germany and WEST VALLEY CITY, Utah – Oct. 14, 2025 – Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in cancer care, and Nusano, a physics company transforming the production of radioisotopes, today announced the signing of a […]
Ariceum Therapeutics Data at the 2025 European Association of Nuclear Medicine Annual Congress Further Supports the Advancement of 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer and Merkel Cell Carcinoma
Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study design of 225Ac-SSO110 in patients with ES-SCLC or MCC 225Ac-SSO110 achieves superior pharmacokinetics with minimal re-distribution of Actinium-225 daughter isotopes and 100% survival in preclinical studies Initial safety data from SANTANA-225 expected in 2026 Berlin, Germany, 9 October 2025 – Ariceum Therapeutics (Ariceum), a targeted […]
Ariceum Therapeutics Appoints David Schilansky as Chief Executive Officer and Announces New Leadership to Advance Next Phase of Development
David Schilansky transitions to CEO, bringing 25 years of company-building, scaling and financing to advance Ariceum’s pipeline of novel radiotherapeutics Initiation of Phase 1/2 SANTANA-225 study of 225Ac-SSO110 Extensive stage small cell lung cancer (ES-SCLC) and Merkle cell carcinoma (MCC) by 2H 2025; initial data expected in 2026 Berlin, Germany, 26 August 2025 – Ariceum Therapeutics […]
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy
Berlin, Germany, 6 February 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC).
FDA Clears Ariceum Therapeutics’ 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma
Berlin, Germany, 14 January 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to commence a Phase I/II clinical trial (‘SANTANA-225’) of its proprietary radiolabelled peptide, 225Ac-SSO110, in patients with small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC).